Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / PEG-MGF
Not FDA-approvedPreclinical
PEG-MGF
ALSO KNOWN ASPegylated mechano growth factor
A marketed IGF-1-related research peptide for which FDA found no human exposure data.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed for subcutaneous or intramuscular injection; neither is approved
04DOSE BASISReported community use only
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What PEG-MGF is.
A pegylated analog marketed around a proposed muscle-specific IGF-1 splice variant. Product naming, identity and biological relevance are major problems.
HOW IT IS THOUGHT TO WORK
Claimed to influence satellite cells and muscle repair; the consumer narrative extends far beyond validated human data.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established human muscle-growth or recovery benefit
- Hypertrophy
- Injury repair
- Safe injection
- Any standardized human protocol
Evidence grade: Preclinical. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Reported community use onlyMost commonly reported community range: 200–400 mcg per injection, 1–2 times weekly for 4–8 weeks. FDA has identified no human exposure data for PEG-MGF, so this is self-reported market practice—not an FDA-approved dose or human clinical-research regimen.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Typically reported as 1–2 injections weekly for 4–8 weeks.
- How to interpret it
- FDA reports no identified human exposure data. These numbers are anonymous self-reports and vendor conventions, not study doses; the claimed multi-day half-life is not established in people.
- Route
- Marketed for subcutaneous or intramuscular injection; neither is approved
- Duration
- Community-reported cycles: 4–8 weeks; no established course
- Men & women
- No human pharmacokinetic, safety or sex-specific dosing data exist.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- No monitoring plan can compensate for absent human exposure data
SAFETY
Risks, red flags and reasons to avoid it.
- Potential immunogenicity
- Complex peptide characterization and impurities
- Unknown systemic growth effects
- Sterility and mislabeling risk
- Human use
- Self-injection
- Combining with IGF-1 or GH secretagogues
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Research-chemical/gray-market sales; no FDA-approved product.
When human exposure data are absent, detailed vendor protocols create an illusion of precision rather than real medical knowledge.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP